Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
41.2 USD | -0.68% | +0.78% | -19.70% |
06-14 | Bristol Myers: FDA approval for treatment | CF |
06-13 | Bristol-Myers Squibb's Augtyro Gets FDA Accelerated Approval for Treatment of Solid Tumors | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.70% | 84.08B | |
+50.70% | 795B | |
+41.96% | 627B | |
-7.15% | 350B | |
+18.77% | 328B | |
+8.79% | 294B | |
+18.02% | 245B | |
+1.27% | 222B | |
+11.95% | 215B | |
+3.68% | 160B |
- Stock Market
- Equities
- BMY Stock
- News Bristol-Myers Squibb Company
- Bristol-Myers Squibb Says US FDA Reassigns Action Date Subcutaneous Nivolumab